Algorithm 1 Moment Matching Algorithm for Estimating EVSI

- 1: **Input:** Number of outer samples *K*, number of inner samples *L*
- 2: **Output:** Estimated EVSI
- 3: Initialize NMB_{outer} $\leftarrow 0$ and NMB_{baseline} $\leftarrow 0$
- 4: **for** k = 1 to *K* **do**
- 5: Sample θ_k from the prior distribution $p(\theta)$
- 6: Generate data x_k from the likelihood $p(X|\theta = \theta_k)$
- 7: Approximate the posterior $p(\theta|x_k)$ using moment matching:
- 8: Compute the sample mean $\hat{\mu}_k$ and sample covariance $\hat{\Sigma}_k$ of the posterior samples $\theta_{l,k}$ given x_k
- 9: NMB_{inner,k} $\leftarrow 0$
- 10: **for** l = 1 to L **do**
- 11: Sample $\theta_{l,k}$ from $\mathcal{N}(\hat{\mu}_k, \hat{\Sigma}_k)$
- 12: Compute NMB $(j, \theta_{l,k}|WTP_{DALY}, WTP_{Elimination})$ for each $j = \{1, 2, \dots, J\}$
- 13: $\text{NMB}_{\text{inner},k} \leftarrow \text{NMB}_{\text{inner},k} + \frac{1}{L} \max_{j=\{1,2,\cdots,J\}} \text{NMB}(j, \theta_{l,k})$
- 14: **end for**
- 15: $\text{NMB}_{\text{outer}} \leftarrow \text{NMB}_{\text{outer}} + \frac{1}{K}\text{NMB}_{\text{inner},k}$
- 16: **end for**
- 17: Estimate the maximum expected NMB without additional data:
- 18: **for** *i* = 1 to *K* **do**
- 19: Sample θ_i from the prior distribution $p(\theta)$
- 20: Compute NMB $(j, \theta_i | WTP_{DALY}, WTP_{Elimination})$ for each $j = \{1, 2, \dots, J\}$

21: NMB_{baseline} \leftarrow NMB_{baseline} + $\frac{1}{K} \max_{j=\{1,2,\dots,J\}} \text{NMB}(j,\theta_i)$

- 22: **end for**
- 23: Compute EVSI:
- 24: $E\hat{V}SI = NMB_{outer} NMB_{baseline}$
- 25: **Return** EVSI

Algorithm 2 Compute EVSI using LOT + PCA + LDA

- Input: Data matrices {μ_i}^N_{i=1}, Reference measure σ, Class labels {y_i}^N_{i=1}, Number of PCA components p, Number of simulated datasets M, Utility function U(ŷ_j, y_j) such that U(ŷ_j, y_j) = 1 if ŷ_j = y_j, else 0.
- 2: Output: EVSI estimate
- 3: Step 1: Compute the Linear Optimal Transport (LOT)
- 4: **for** i = 1 to *N* **do**
- 5: Compute optimal transport map T_i^* between σ and μ_i such that:

$$d_{W^p}(\mu_i,\sigma) := \left(\int_{\Omega} |x - T_i^*(x)|^p \,\mathrm{d}\sigma(x)\right)^{\frac{1}{p}}$$

- 6: Compute the projections $P(\mu_i) = T_i^* \text{Id}$, where Id is the identity map.
- 7: **end for**
- 8: Step 2: Apply PCA on the projections
- 9: Construct matrix $\mathbf{P} \in \mathbb{R}^{N \times d}$ where each row is $\{P(\mu_i)\}_{i=1}^N$.
- 10: Center the data: $\mathbf{P}_c \leftarrow \mathbf{P} \mathbb{E}(\mathbf{P})$.
- 11: Compute the covariance matrix: $\mathbf{C} \leftarrow \frac{1}{N} \mathbf{P}_c^T \mathbf{P}_c$
- 12: Compute eigenvalues and eigenvectors of C
- 13: Select top *p* dominant eigenvectors to form the PCA projection matrix $\mathbf{P}_{PCA} \in \mathbb{R}^{d \times p}$
- 14: Project the centered data onto PCA components: $\mathbf{X} = \mathbf{P}_c \mathbf{P}_{PCA}$.
- 15: Step 3: Train the LDA classifier
- 16: Train the LDA classifier once using the PCA components for different L = 20%, 40%, 60%, 80% of the data i.e., $\{\mathbf{X}_i\}_{i=1}^L$ with the class labels $\{y_i\}_{i=1}^L$ where *L* is the size of the training dataset.
- 17: **Return** Predicted labels $\{\hat{y}_j\}_{j=1}^V$ on the test data $\{\mathbf{X}_j\}_{j=1}^V$ where V = N L is the size of the test dataset. Decision boundary giving the estimate for WTP_{Elimination} for 65% MDA coverage.
- 18: Step 4: Evaluate Utility function
- 19: Compute expected utility $EU_{current} = \frac{1}{V} \sum_{j=1}^{V} U(\hat{y}_j, y_j).$
- 20: Step 5: Train on the Augmented Dataset
- 21: **for** k = 1 to *M* **do**
- 22: Generate bootstrap samples from the LOT projections $\{P(\mu_i)\}_{i=1}^N$, namely $\{P'(\mu_i)\}_{i=1}^N$.
- 23: Follow Steps 2-3 and compute the PCA components for the new bootstrap sample resulting in $\{\mathbf{X}'_i\}_{i=1}^L$ with class labels $\{y'_i\}_{i=1}^L$. Train LDA on this bootstrapped dataset for L = 20%, 40%, 60%, 80%.
- 24: Obtain predicted class labels $\{\hat{y}'_j\}_{j=1}^V$ for test data $\{\mathbf{X}'_j\}_{j=1}^V$ where V = N L.
- 25: Compute expected utility for the *k*-th bootstrap sample: $EU_{new,k} = \frac{1}{V} \sum_{j=1}^{V} U(\hat{y}'_j, y'_j).$
- 26: **end for**
- 27: Step 6: Compute EVSI
- 28: Compute average expected utility with additional data: $EU_{sample} = \frac{1}{M} \sum_{k=1}^{M} EU_{new,k}.$
- 29: Compute EVSI: EVSI = $EU_{sample} EU_{current}$.
- 30: Return EVSI

1105 Appendix B. Supplementary Material: Additional Results

Table B.1: Probability of Elimination for different stopping thresholds for TAS sampling for people aged ≥ 20 years (adults)

		Probabi	ility of Elimination for diff	erent stopping thresholds f	for TAS
MDA coverage	Mean baseline prevalence	(<0.5%)	(<1%)	(<2%)	(<5%)
	5-10%	91.8% (90.2 - 92.28)	83.8% (80.97 - 84.8)	81.47% (80.23 - 82.27)	72.16% (70.67 - 72.28)
80%	10-20%	77.28% (75.56 - 78.23)	71.03% (70.03 - 68.97)	65.88% (64.26 - 67.28)	61.78% (60.23 - 62.97)
	20-30%	67.68% (63.24 - 68.52)	65.91% (64.06 - 67.28)	63.96% (61.34 - 65.34)	61.51% (60.23 - 63.23)
	5-10%	90.7% (88.13 - 92.02)	87.65% (85.34 - 89.70)	85.43% (82.02 - 89.22)	80.03% (79.89 - 82.27)
65%	10-20%	75.12% (72.02 - 77.36)	70.10% (69.89 - 72.81)	65.76% (64.83 - 67.86)	60.47% (58.96 - 62.21)
	20-30%	65.63% (62.54 - 68.35)	62.73% (60.83 - 69.43)	60.15% (59.24 - 62.35)	59.24% (54.10 - 62.37)

Table B.2: Probability of Elimination for different stopping thresholds for TAS sampling for people aged \geq 5 years (including, children)

		Probability of Eliminatio	robability of Elimination for different stopping thresholds for TAS									
MDA coverage	Mean baseline prevalence	(<0.5%)	(<1%)	(<2%)	(<5%)							
	5-10%	89.2% (87.22 - 91.23)	80.05% (79.23 - 81.28)	75.04% (72.28 - 78.97)	68.08% (65.07 - 67.83)							
80%	10-20%	72.63% (70.86 - 77.53)	62.04% (60.23 - 63.27)	57.33% (54.62 - 59.90)	52.49% (50.23 - 56.24)							
	20-30%	55.99% (51.02 - 56.87)	53.5% (50.23 - 58.75)	50.5% (48.23 - 52.55)	48.23% (45.23 - 50.12)							
	5-10%	85.23% (82.78 - 89.23)	78.23% (76.89-80.23)	72.25% (70.02 - 75.23)	65.13% (62.34-68.23)							
65%	10-20%	72.15% (71.03 - 75.45)	60.23% (58.89 - 63.23)	55.13% (52.82-57.86)	51.23% (50.96 - 56.87)							
	20-30%	55.23% (50.54 - 58.35)	51.23% (50.83 - 56.43)	48.23% (46.24 - 50.35)	46.73% (44.78 - 48.87)							

Table B.3: Probability of Elimination for different stopping thresholds for TAS sampling for everyone eligible

		Probability of Eliminatic	Probability of Elimination for different stopping thresholds for TAS									
MDA coverage	Mean baseline prevalence	(<0.5%)	(<1%)	(<2%)	(<5%)							
	5-10%	90.7% (87.23 - 92.18)	81.76% (80.17 - 83.63)	80.07% (78.86 - 82.27)	71.58% (70.57 - 72.28)							
80%	10-20%	74.57% (75.56 - 78.23)	71.03% (70.03 - 68.97)	65.88% (64.26 - 67.28)	61.78% (60.23 - 62.97)							
	20-30%	60.08% (59.84 - 62.52)	57.64% (55.23 - 60.12)	54.23% (51.24 - 57.98)	50.23% (49.93 - 53.29)							
	5-10%	88.13% (83.23 - 90.02)	78.23% (75.34-79.70)	70.24% (69.75 - 73.25)	68.23% (65.89-70.87)							
65%	10-20%	72.13% (70.02-77.36)	65.52% (60.23 - 68.87)	60.23% (59.83-62.86)	58.23% (55.86 - 60.81)							
	20-30%	58.23% (57.04 - 60.05)	55.23% (54.03 - 57.89)	52.12% (50.04 - 55.85)	48.23% (46.23 - 50.91)							

		Total	MDA ro	ounds (T	AS sur	veys)			
Mean baseline prevalence	Total Number of MDA rounds (TAS surveys)	veys) (<0.5%) (<1%) (<2%) ((<5%)					
	MDA coverage	80%	65%	80%	65%	80%	65%	80%	65%
	5 rounds (3 surveys)	80	76	86	80	92	88	93	90
5-10%	\geq 7 rounds (4 surveys)	20	24	14	20	8	12	7	10
	7 restart (5 surveys)	0	0	0	0	0	0	0	0
	5 rounds (3 surveys)	82	70	88	72	90	77	88	82
10-20%	\geq 7 rounds (4 surveys)	18	26	12	24	10	17	9	12
	7 restart (5 surveys)	0	4	0	4	0	6	3	6
	5 rounds (3 surveys)	45	35	43	38	44	39	46	41
20-30%	\geq 7 rounds (4 surveys)	50	57	50	55	46	54	45	48
	7 restart (5 surveys)	5	8	7	7	10	7	9	11

Table B.4: Total MDA rounds with TAS surveys for different MDA coverage levels sampling for people aged ≥ 20 years and above.

Table B.5: Total MDA rounds with TAS surveys for different MDA coverage levels sampling for people aged \geq 5 years and above.

		Total	MDA ro	ounds (T	'AS surv	veys)				
Mean baseline prevalence	Total Number of MDA rounds (TAS surveys)	(<0.5%	%)	(<1%))	(<2%))	(<5%)	(<5%)	
	MDA coverage	80%	65%	80%	65%	80%	65%	80%	65%	
	5 rounds (3 surveys)	78	74	82	80	86	82	88	84	
5-10%	\geq 7 rounds (4 surveys)	22	26	18	20	14	20	12	0	
	7 restart (5 surveys)	0	0	0	0	0	0	0	0	
	5 rounds (3 surveys)		68	85	70	87	77	88	80	
10-20%	\geq 7 rounds (4 surveys)	18	28	15	26	13	18	8	13	
	7 restart (5 surveys)	0	4	0	4	0	5	4	7	
	5 rounds (3 surveys)	37	36	42	39	41	41	40	43	
20-30%	\geq 7 rounds (4 surveys)	54	52	46	52	43	46	42	42	
	7 restart (5 surveys)	9	12	12	9	16	13	18	15	

Table B.6: Total MDA rounds with TAS surveys for different MDA coverage levels sampling everone eligible in the population

		Total	MDA ro	ounds (T	AS sur	veys)			
Mean baseline prevalence	Total Number of MDA rounds (TAS surveys)	(<0.5%)		(<1%)		(<2%)		(<5%)	
	MDA coverage	80%	65%	80%	65%	80%	65%	80%	65%
	5 rounds (3 surveys)	85	80	88	82	86	83	87	85
5-10%	\geq 7 rounds (4 surveys)	15	20	9	12	7	9	5	9
	7 restart (5 surveys)		0	3	6	7	8	8	6
	5 rounds (3 surveys)	78	63	76	65	77	68	80	72
10-20%	\geq 7 rounds (4 surveys)	18	32	18	28	15	23	11	17
	7 restart (5 surveys)	4	5	6	7	8	9	9	11
	5 rounds (3 surveys)	41	35	40	36	42	42	44	41
20-30%	\geq 7 rounds (4 surveys)	52	59	51	55	47	49	43	47
	7 restart (5 surveys)	7	6	9	9	11	9	13	12

Table B.7: Expected incremental net monetary benefit (in dollars) of switching from <1% threshold to <0.5% threshold in the TAS for each setting for a sample of adults aged 20 years and above. Note: The comparator for computing the EINMB is the <1% threshold in people aged 5 years and above for the individual baseline prevalence and MDA coverage of the total population. This has been chosen for a range of WTP for DALY averted and probability of elimination so that we can estimate the cost-effectiveness of the threshold at different known baseline prevalence and MDA coverage.

	(WTP pe	(WTP per DALY averted)									
Baseline Prevalence	\$ 500		\$2500		\$5000						
	MDA Co	overage	MDA C	MDA Coverage		overage					
	80%	65%	80%	65%	80%	65%					
Willingness to pay \$0	per 1% in	crease in th	e probabil	lity of elin	ination to	switch thresholds					
5-10%	\$3,286	\$189	\$1,009	-\$1589	\$5,79	-\$3503					
10-20%	\$5,575	\$275.32	\$3,781	-\$2589	\$1,334	-\$2892					
20-30%	\$8,373	-\$102	\$6,823	-\$803	\$3,534	-\$1106					
Willingness to pay \$1	0,000 per	1% increase	e in the pro	obability o	f eliminat	ion to switch thresholds					
5-10%	\$3,286	\$5189	\$1,009	\$3,411	\$5,79	\$1497					
10-20%	\$5,575	\$5275	\$3,781	\$2,411	\$1,334	\$2108					
20-30%	\$8,373	\$4898	\$6,823	\$5198	\$3,534	\$5898					
Minimum willingness	to pay \$5.	,000 per 1%	b increase	in probabi	lity of elir	nination to switch thresholds					
5-10%	\$3,286	\$3189	\$1,009	\$1,411	\$5,79	\$497					
10-20%	\$5,575	\$3275	\$3,781	\$1411	\$1,334	\$1,008					
20-30%	\$8,373	\$2398	\$6,823	\$2197	\$3,534	\$2,894					

Table B.8: Expected incremental net monetary benefit (in dollars) of switching from <1% threshold to <0.5% threshold in the TAS for each setting when everyone eligible in the population has been considered. Note: The comparator for computing the EINMB is the <1% threshold in people aged 5 years and above for the individual baseline prevalence and MDA coverage of the total population. This has been chosen for a range of WTP for DALY averted and probability of elimination so that we can estimate the cost-effectiveness of the threshold at different known baseline prevalence and MDA coverage.

	(WTP p	(WTP per DALY averted)										
Baseline Prevalence	\$ 500		\$2500		\$5000							
	MDA C	overage	MDA C	MDA Coverage		overage						
	80%	65%	80%	65%	80%	65%						
Willingness to pay \$0	per 1% in	crease in	the probal	bility of eli	imination	to switch thresholds						
5-10%	\$4,398	\$979	\$2,469	-\$2569	\$8,29	-\$3593						
10-20%	\$6,695	\$459	\$5281	-\$2793	\$1,524	-\$3092						
20-30%	\$9,203	-\$112	\$7,243	-\$1243	\$4,864	-\$836						
Willingness to pay \$10	0,000 per	1% increa	ise in the p	probability	of elimin	ation to switch thresholds						
5-10%	\$4,398	\$5979	\$2,469	\$2,431	\$8,29	\$1407						
10-20%	\$6,695	\$5459	\$5281	\$2,207	\$1,524	\$1907						
20-30%	\$9,203	\$4888	\$7,243	\$3757	\$4,864	\$4164						
Minimum willingness	to pay \$5	,000 per 1	1% increas	se in proba	bility of e	limination to switch thresholds						
5-10%	\$4,398	\$3979	\$2,469	\$431	\$8,29	\$407						
10-20%	\$6,695	\$3459	\$5281	\$207	\$1,524	\$9,08						
20-30%	\$9,203	\$2888	\$7,243	\$1757	\$4,864	\$3,164						

Baseline Prevalence	Number of Training Sample	Classi	fication	Error o	n test data
		0.5%	1%	2%	5%
5-10%	20%	0.2	0.27	0.35	0.37
	50%	0.17	0.21	0.27	0.32
	60%	0.10	0.12	0.19	0.23
	80%	0.05	0.07	0.09	0.12
10-20%	20%	0.42	0.46	0.49	0.51
	50%	0.37	0.43	0.45	0.48
	60%	0.32	0.35	0.37	0.39
	80%	0.21	0.24	0.29	0.31
20-30%	20%	0.59	0.64	0.67	0.72
	50%	0.52	0.43	0.37	0.35
	60%	0.32	0.35	0.39	0.42
	80%	0.33	0.37	0.42	0.44

Table B.9: Classification error on test data using LDA for different values of the training sample size and different thresholds using point cloud data of costs and DALYs averted using fixed WTP for DALYs averted for 80% MDA coverage for sample of adults.

Table B.10: Classification error on test data using LDA for different values of the training sample size and different thresholds using a point cloud of costs with DALYs averted, Probability of elimination using estimated WTP for 1% increase in probability of elimination for 65% MDA coverage using a sample of adults.

Baseline Prevalence	Number of Training Sample	Classif	fication	Error o	n the test data
		0.5%	1%	2%	5%
5-10%	20%	0.3	0.34	0.37	0.41
	50%	0.27	0.31	0.35	0.39
	60%	0.23	0.27	0.29	0.31
	80%	0.15	0.17	0.19	0.22
10-20%	20%	0.43	0.47	0.52	0.57
	50%	0.41	0.43	0.47	0.52
	60%	0.37	0.39	0.41	0.43
	80%	0.35	0.37	0.39	0.41
20-30%	20%	0.56	0.61	0.63	0.62
	50%	0.42	0.43	0.53	0.57
	60%	0.35	0.37	0.41	0.47
	80%	0.27	0.33	0.37	0.44

Table B.11: Comparison of the EVSI per person for Moment Matching (MM), Nested Monte Carlo (MC) and LOT+PCA+LDA methods for 65% MDA coverage in 5-10% mf baseline prevalence

Threshold (%)	Sample Size (500)			Sample	Size (1000))	Sample Size (1500)		
	MC	MM	LOT+LDA	MC	MM	LOT+LDA	MC	MM	LOT+LDA
EVSI per Person									
<0.5%	250	200	220	285	270	276	295	300	310
<1%	210	180	185	263	250	255	277	280	287
<2%	152	130	145	185	170	165	217	220	229
<5%	120	100	110	155	140	145	175	180	192
Computational '	Time								
<0.5%	>8 hrs	≈2 min	≈1 min	>8 hrs	≈2 min	≈1 min	>8 hrs	≈2 min	≈1 min
<1%	>8 hrs	≈2 min	≈1 min	>8 hrs	≈2 min	≈1 min	>8 hrs	≈2.5 min	≈1 min
<2%	>8 hrs	≈2 min	≈1 min	>8 hrs	≈2 min	≈2 min	>8 hrs	≈2 min	≈2 min
<5%	>8 hrs	≈2.5 min	≈2 min	>8 hrs	≈3 min	≈2 min	>8 hrs	≈3 min	≈2 min

Thrashold (%)	Sample	Size (500)		Sample	Size (1000))	Sample	Size (1500)	
	MC	MM	LOT+LDA	MC	MM	LOT+LDA	MC	MM	LOT+LDA
EVSI per Person	n								
<0.5%	197	175	185	245	230	237	272	270	275
<1%	182	163	173	222	210	215	225	220	227
<2%	140	120	134	162	160	175	175	170	172
<5%	105	80	98	125	110	119	157	170	153
Computational '	Time								
<0.5%	>8 hrs	≈2 min	≈1 min	>8 hrs	≈2 min	≈1 min	>8 hrs	≈2 min	≈1 min
<1%	>8 hrs	≈2 min	≈1 min	>8 hrs	≈2 min	≈1 min	>8 hrs	≈2.5 min	≈1 min
<2%	>8 hrs	≈2 min	≈1 min	>8 hrs	$\approx 2 \min$	≈2 min	>8 hrs	≈2 min	≈2 min
<5%	>8 hrs	≈2.5 min	≈2 min	>8 hrs	$\approx 3 \min$	≈2 min	>8 hrs	≈3 min	$\approx 2 \min$

Table B.12: Comparison of the EVSI per person for Moment Matching (MM), Nested Monte Carlo (MC) and LOT+PCA+LDA methods for 65% MDA coverage in 10-20% mf baseline prevalence

 Table B.13: Comparison of the EVSI per person for Moment Matching (MM), Nested Monte Carlo (MC) and LOT+PCA+LDA methods for 65% MDA coverage

 in 20-30% mf baseline prevalence

Threshold (%)	Sample Size (500)			Sample Size (1000)			Sample Size (1500)			
	MC	MM	LOT+LDA	MC	MM	LOT+LDA	MC	MM	LOT+LDA	
EVSI per Person										
<0.5%	165	157	160	182	175	177	192	180	185	
<1%	115	103	109	123	110	115	130	125	127	
<2%	95	87	92	105	93	100	120	110	117	
<5%	63	52	57	87	75	82	107	98	105	
Computational Time										
<0.5%	>8 hrs	≈2 min	≈1 min	>8 hrs	≈2 min	≈1 min	>8 hrs	≈2 min	≈1 min	
<1%	>8 hrs	≈2 min	≈1 min	>8 hrs	≈2 min	≈1 min	>8 hrs	≈2.5 min	≈1 min	
<2%	>8 hrs	≈2 min	≈1 min	>8 hrs	≈2 min	≈2 min	>8 hrs	≈2 min	≈2 min	
<5%	>8 hrs	≈2.5 min	≈2 min	>8 hrs	≈3 min	≈2 min	>8 hrs	≈3 min	≈2 min	

1106Appendix C. Supplementary Material :Transmission1107Model Details1127

same for both at 11.3 which was estimated as a fit to a dataset from India [13]. We further assume ADL to occur about twice per year (0-7 times) in 70% (45–90%) of hydrocele patients, and four (0-7 times) times annually for 95% (90–95%) of patients with lymphoedema [14].

The codes used in this paper, including the R version of the_{129} TRANSFIL model is available from https://github.com/₁₁₃₀ mca52/Codes_JTB.git.

Value/Scenario
5 -10%, 10-20%, 20-30%
IA
Annual
65%, 80%
0.2806 - 0.5351
<0.5%,<1%,<2%,<5%
Culex
0.01 - 0.1
0 - 1200
0
2 years
5-15
0.37
4.395
0.055
5
1
0.414
0.32
0.00275
0.0104
0.1
0.00167
0.99
0.35
9
0.97
0.02
0.71

1128

1111Appendix C.1. Calculation of the prevalence of morbidity (hy11311112drocele, lymphoedema and ADL)1132

Each individual is assigned a susceptibility to having hydro-¹¹³³ 1113 cele (if female, this = 0) and lymphoedema. These susceptibil-1114 1135 ities are drawn from a gamma distribution with a specific shape 1115 gl and rate 1/gl (giving the distribution a mean of 1). This sus-1116 ceptibility is drawn at birth and is never changed for the in1136 1117 dividual. To assess if someone has one of these sequelae, we¹³⁷ 1118 multiply their susceptibility to the sequelae by the total worms¹³⁸ 1119 they have had over their lifetime. If this value is greater than139 1120 a chosen number, then they will be designated as displaying¹⁴⁰ 1121 this sequela. A consequence of this is that once a person has d¹⁴¹ 1122 sequela, they will always have it. 1123

For lymphoedema the shape parameter is 0.0033 and for hy₁₁₄₂ drocele it is 0.02 [13]. The number they are compared to is the₁₄₃ Appendix C.2. Calculation of the DALY averted for morbidity In order to estimate the burden of morbidity caused by lymphatic filariasis, we propose the following DALY framework. The burden of the disease can be mathematically estimated as follows.

$$DALY = YLL + YLD \tag{C.1}$$

where YLL is the years lost due to premature death of the disease and YLD is the years lived with disability caused by the disease. We modified this mathematical formula for the estimating the burden of morbidity caused by filariasis as a cause. Consequently, we compute the two components of DALYs as follows:

$$YLD = Prevalence_{Morbidity} \times dw$$
(C.2)

where $Prevalence_{Morbidity}$ is the prevalence of morbidity (computed as mentioned in Appendix C.1) and dw is the published

disability weights for lymphoedema, hydrocele and ADL. [21].Now, we consider

$$YLL = N \times L \tag{C.3}$$

where N is the number of deaths caused by the burden of the 1146 disease and L is the standard expected life expectancy at the 1147 age of death. According to GBD, no deaths occurred as a result 1148 of the burden of morbidity caused by lymphatic filariasis. In ad-1149 dition, according to the WHO, although filariasis is one of the 1150 leading causes of disability, death from filariasis is rare. There-1151 fore, we will assume N \sim 0. This in turn leads to the years lost 1152 due to premature death as zero. Hence, the estimated DALY 1153 burden due to morbidity is simply the prevalence of morbidity 1154 (computed from Appendix C.1) times the disability weights 1155 [26]: 1156

$$DALY = YLD = Prevalence_{Morbidity} \times dw$$
 (C.4)

¹¹⁵⁷ Therefore, the DALYs averted is computed as,

1158 Appendix C.3. Calculation of the total costs

¹¹⁵⁹ The total costs are computed as indicated below,

Total costs =
$$w_1 \times$$
 Total MDA rounds
+ $w_2 \times$ Total TAS surevys conducted (C.6)

where w_1 [47] and w_2 [7] are the estimated cost weightings 1160 computed in accordance with the current purchasing power par-1161 ity in the US \$. The total MDA rounds and total TAS surveys 1162 conducted are computed from the TRANSFIL simulations by 1163 keeping a counter for each simulation under the different sce-1164 narios. The expected estimated cost weightings of MDA [47] 1165 and TAS surveys [7] (excluding the costs for rapid diagnostic 1166 tests RDT) for LF programs with annual treatment from the per-1167 spective of the endemic country government cover financial and 1168 economic costs. The financial costs are the costs of all inputs 1169 purchased in cash for MDA, including purchased MDA drugs, 1170 materials and supplies, ministry of health personnel salaries, 1171 and per diem payments for community drug distributors. Eco-1172 nomic costs also include the costs of donated drugs for MDA. 1173

Table C.15: Table with the definitions of the ke	v acronyms used in the manuscript.	Adapted from Box 1 in [3].
racie criter racie millione deminicione de		

Table C.15. Table with the	deminitions of the key actonyms used in the manuscript. Adapted nom box 1 m [5].	
Terminologies	Description	Page Defined
	A method to compare the relative costs and outcomes (effects) of different interventions or	1 2 2 11
CEA (Cost-Effectiveness Analysis)	treatments	pg. 1,2,3,11
	The number of years lost due to premature death of the disease and the years lived with	
DALYs (Disability Adjusted Life Years)	disability caused by the disease	pg. 1,2,3,4,7,8,9,10,11
	A factor (between 0 and 1) which is used to calculate the number of years lost due to dis	
Disability weights	A factor (between 0 and 1) which is used to calculate the number of years lost due to dis-	pg. 7,8
	ability that accounts for the sevenity of the disease.	
	The mean of the difference in NMB between alternative interventions, a positive incremen-	
	tal NMB indicating that the intervention is cost-effective compared with the alternative at	
EINMB (Expected Incremental Net Monetary Benefit)	the given willingness-to-pay threshold. In this case, the incremental cost to derive the incre-	pg. 3,4,7,9,10,11
	mental benefit is less than the maximum amount that the decision-maker would be willing	
	to pay for this benefit.	
EVDL (Ennersted Value of Deufort Information)	The maximum amount a decision-maker would be willing to pay for perfect information,	450
EVPI(Expected value of Perfect Information)	which would completely eliminate uncertainty.	pg. 4,3,9
	The value of obtaining information that only partially resolves uncertainty, providing some	
EVPPI (Expected Value of Partial Perfect Information)	but not complete clarity	pg. 4,5,9,10
	The value of acquiring information through sampling or additional data collection to reduce	
EVSI (Expected Value of Sample Information)	uncertainty in decision making	pg. 3,5,6,7,9,10
	The circle in the control of the con	
	The ratio of change in costs (ΔC) to the change in health impacts (ΔE). In this manuscript,	
ICER (Incremental Cost-Effective Ratio)	we consider the health impacts due to the DALYs averted for morbidity and the probability	pg. 1,2,3,4
	of unit increase in elimination.	
	A mathematical approach for finding the most cost-effective way to transport resources from	
LOT (Linear Optimal Transport)	one distribution to another while minimizing the total transport cost. Also known as 'Linear	pg. 1,3,5,6,7,8,9,10,11
	Wasserstein Framework'	
	A statistical technique (supervised classifier) used for classifying data by identifying linear	
LDA (Linear Discriminant Analysis)	combinations of features that most effectively distinguish between different classes	pg. 1,8,9,10
	The prevalence or incidence of disease or illness within a population often measured by the	
	frequency and covaries of health related symptoms. In this study, lymphoodems refers to	
Morbidity	inequency and severity of nearth-related symptoms. In this study, tymphoedema refers to	pg. 1,3,7,8,9,10,11
	the improper functioning of the lymph system that results in fluid collection and swelling;	10
	hydrocele refers to the swelling of the scrotum due to infection	
	A method of preventive chemotherapy involving the distribution of anthelminthic drugs to	
MDA (Mass Drug Administration)	all eligible individuals within a specified area (such as a state, region, province, district,	pg. 2,3,7,8,9,10,11
	subdistrict, or village) on a routine basis, regardless of their individual infection status.	
MDA coverage	The proportion of eligible people in the population who receive MDA.	pg. 3,7,8,9,10,11
	A summary statistic that represents the value of an intervention (in this case, stopping and	10 / / / /
NMB (Net Monetary Benefit)	restarting MDA) in monetary terms when a willingness to pay threshold for a unit of benefit	ng 4
This (The Monetary Benene)	(DALVs averted for morbidity or 1% increase in probability of local elimination) is known	P5
	A dimensionality reduction technique that transforms data into a set of orthogonal compo	
PCA (Principal Component Analysis)	A dimensionality reduction technique that transforms data into a set of orthogonal compo-	pg. 7,9,10
	nents that capture the most variance in the data.	
	A method that examines how uncertainty in the model's input parameters affects the out-	
Probabilistic Sensitivity Analysis (PSA)	comes by running multiple Monte Carlo simulations by varying the input parameters ac-	pg. 2,5
	cording to their probability distributions.	
	A prevalence threshold which is used to determine whether MDA can stop or if further	
Stopping threshold	rounds are required. The WHO recommended stopping threshold is <1% mf in children	pg. 1,2,3,7,8,9,10,11
	aged 5 years and above or $<2\%$ Ag in children aged 6-7 years old.	
	A survey designed to measure whether evaluation units have lowered the prevalence of in-	
TAS (Transmission Assessment Surveys)	fection to a level where recrudescence is unlikely to occur even in the absence of MDA	pg 23781011
	interventions	Pg: 2,0,7,0,10,11
	The framework used to assess the banafit gained from obtaining additional information to	
VoI (Value of Information)	improve desigion making under uncertainty	pg. 2,3,7
	miprove decision-making under uncertainty.	
	A measure of the difference between two probability distributions, defined as the minimum	
$d_{W^p}(\mu, \nu)$ (Wasserstein distance)	cost of transporting mass from one distribution to another, where the cost is quantified by	pg. 5,6,11
	the <i>p</i> th power of the Euclidean distance function between points in the distributions	
	The amount of money the decision maker (individual, organization, or government) would	
WTP (Willingness To Pay)	be willing to spend per unit of clinical effectiveness (in this case, DALYs averted for mor-	ng 1347801011
will (willingliess to ray)	bidity or 1% increase in probability of local elimination). In this study, we rely on the	pg. 1,5,4,7,0,7,10,11
	willingness to pay per capita government expenditure for three different example countries	
	The quantity of filarial worms present within a host organism, typically measured by the	2.0
worm burden	number or mass of worms within a specific anatomical location or system	pg. 2,8